• Tito R Mendoza, Xin Shelley Wang, Loretta A Williams, Qiuling Shi, Elisabeth G Vichaya, Patrick M Dougherty, Sheeba K Thomas, Emre Yucel, Christel C Bastida, Jeanie F Woodruff, and Charles S Cleeland.
• Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: tmendoza@mdanderson.org.
• J Pain. 2015 Oct 1; 16 (10): 1032-43.

UnlabelledVarious sensory and motor effects are associated with cancer treatment-induced peripheral neuropathy. The current method for capturing the multifaceted nature of neuropathy includes a combination of objective tests, clinician evaluation, and subjective patient report, an approach that is often not logistically feasible, especially for multisite trials. We report the performance of a brief yet comprehensive, easily administered measure, the Treatment-Induced Neuropathy Assessment Scale (TNAS), for assessing the severity and course of neuropathy across various cancer treatments. Data were derived from 4 longitudinal or cross-sectional patient cohorts (N = 573). Patients with multiple myeloma treated primarily with bortezomib and patients with colorectal cancer receiving oxaliplatin evaluated candidate items. Cognitive debriefing showed that all items were easy to understand, and this preliminary TNAS demonstrated reliability, validity, and sensitivity. Numbness/tingling was the most severe item, regardless of therapeutic agent. Although numbness and general pain were moderately correlated, patients perceived them as distinct. Most TNAS items were more severe at follow-up, demonstrating the sensitivity of the instrument to accumulating dose. The TNAS will be refined with further patient input, with final psychometric evaluation conducted in a new patient sample receiving treatments known to be associated with peripheral neuropathy. The nonpainful component of neuropathy may be more disabling than the pain component.PerspectiveOur data suggest that the nonpainful components of neuropathy may be more disabling than the pain component during cancer treatment. Here we report data on sensory and motor symptoms reported by patients receiving neurotoxic cancer therapy, and we detail the development of a neuropathy assessment scale that follows regulatory guidance for patient-reported outcomes.Copyright © 2015 American Pain Society. Published by Elsevier Inc. All rights reserved.

31 keywords...

hide…